MD · Pediatrix Medical Group, Inc.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 4, 2026TL;DR. Pediatrix reported Q2 2026 adjusted EBITDA of $76 million and reaffirmed its full-year 2026 adjusted EBITDA guidance of $280–$300 million, noting stable payor mix, strong RCM collections, and rising acuity, while same-unit patient volumes declined 2% and NICU days fell 3%.
- + Generated $76 million in Q2 adjusted EBITDA, in line with expectations
- + Reaffirmed full-year 2026 adjusted EBITDA guidance of $280–$300 million
- + Repurchased nearly 2 million shares in Q2, bringing total buybacks since August 2025 to 7 million shares and reducing share count to 81 million from 87 million
- + Strong balance sheet with $289 million cash, ~1x leverage, and $126 million operating cash flow supports growth and capital returns
- − Same-unit patient service volumes declined 2%, with NICU days down 3%
- − Management expects full-year 2026 volumes to be flat to slightly down
- − RCM collections tailwind expected to dissipate in the second half of 2026
- − Q2 operating cash flow of $126 million fell from $138 million in the prior-year quarter
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MD
this stock
Pediatrix Medical Group, Inc.
|
$2.14B | +22.0% | -4.9% | 12.6 | 5.8% |
|
HCA
HCA Healthcare, Inc.
|
$96.64B | -6.8% | +7.1% | 15.0 | 2.9% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$29.92B | -13.3% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$20.91B | +30.6% | +0.9% | 10.0 | 2.5% |
|
FMS
Fresenius Medical Care AG
|
$12.08B | -4.9% | +5.9% | — | 0.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MD | +0.7% | -3.4% | +15.4% | +1.4% | +22.0% |
| SPY | +1.2% | +0.6% | +11.6% | +1.6% | +13.6% |
| vs SPY | -0.5% | -4.0% | +3.9% | -0.2% | +8.4% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.